The company believes its product, called Constellation, will differentiate itself from current commercial offerings in terms of throughput and multiplexing capability.
Separate studies in NEJM from Regeneron Pharmaceuticals and Ionis Pharmaceuticals target the ANGPTL3 gene in an effort to develop heart disease treatments.
The DiscovEHR study, conducted by the Regeneron Genetics Center and the Geisinger Health System, uncovered many associations between genetic variants and clinical phenotypes.
Pittsburgh-based Curable is building a coalition to sequence genomes of patients with a rare autoimmune disease of the bile ducts to inform drug development.
